Close Menu

NEW YORK – CareDx said on Friday that it has received the CE mark for its AlloSeq cfDNA kit, making it available to transplant patients and clinicians in Europe.

AlloSeq cfDNA is a kit-based product that is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health, and is run on next generation sequencing platforms. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.